You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox on Tuesdays and Thursdays.
The pharma CEO behind $35 insulin
As I was reporting out a story about insulin pricing, a source asked me a question that stopped me in my tracks: Where did the ubiquitous $35 per month figure come from?
Both President Biden and former President Trump have been eager to claim credit for $35 insulin. The number was included in the Inflation Reduction Act’s Medicare insulin protections, has popped up in states, has been the basis of bills in Congress, and has become the go-to standard for companies’ patient assistance.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect